Abstract library

25 results for "Mazzaferro".
#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters
Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2716 Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report
Introduction: There are no dedicated guidelines for treatment of urothelial NEC given disease rarity. An aggressive approach, including neoadjuvant cisplatin-based chemotherapy + nephroureterectomy and adjuvant platinum-based chemotherapy, is recommended.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Roberta Elisa Rossi
#2784 Predictive Factors of Tumor Recurrence after Radical Surgery for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs): Identification of High-Risk Subgroups
Introduction: There is no proven role for adjuvant medical therapy after curative surgery (R0) for GEP-NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Roberta Elisa Rossi
#2792 Post-Transplant Recurrence of Neuroendocrine Tumors
Introduction: Recurrence after liver transplantation (LT) for metastases from NET is observed in 30-50% of cases at 5 years after LT but management is individualized
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2798 Risk of Pre-Operative Understaging of Duodenal Neuroendocrine Tumors at Conventional Imaging: When Surgery Becomes the First Choice
Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors that can exhibit aggressive behavior, with loco-regional nodes and distant metastases. Pre-treatment staging is the basis for planning either surgical or endoscopic treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: dr Sara Massironi
#473 Succinate Dehydrogenase (SDHB): A New Marker of Malignancy in Midgut Carcinoids?
Introduction: The immunoistochemical (IHC) loss of SDHB expression was reported as a surrogate marker of malignancy in sporadic and familial pheocromocytomas/paragangliomas. SDHB loss is supposed to be tumorigenic (activation hypoxia signals).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Sara Pusceddu
Keywords: SDHB
#480 Immunohistochemical (IHC) Overexpression of Succinate Dehydrogenase (SDHB) as Prognostic Factor in Sporadic Pheochromocytomas/Paragangliomas (P/P)
Introduction: Recently, gene mutations (SDH complex) involved in the pathogenesis of familial P/P have been discovered. These mutations are often associated with SDHB activity loss and activation of hypoxia signals.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Sara Pusceddu
#482 Well-Differentiated Neuroendocrine Tumors (WDNETs) and Carcinoid Syndrome (CS): A Retrospective Analysis of 110 Patients from Istituto Nazionale Tumori Milano
Introduction: CS is characterized by flushing, diarrhea and carcinoid heart disease (CHD) alone or in association.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Sara Pusceddu
#581 Loss of Succinate Dehydrogenase (SDHB) Expression in Midgut Carcinoids as Prognostic Factor: a New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?
Introduction: Gene mutations of SDH complex have been involved in the pathogenesis of cancer cells. These mutations are often associated with loss of activity of SDH subunity B and overexpression of HIF-1a, which play a central role in angiogenesis.
Conference:
Category: Basic
Presenting Author: Dr. Massimo Milione
#645 Loss of Succinate Dehydrogenase (SDHB) in Midgut Carcinoids as Prognostic Factor: A New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?
Introduction: Gene mutations of the succinate dehydrogenase (SDH) complex are involved in the pathogenesis of cancer cells and play a pivotal role in angiogenesis and cell proliferation. The immunoistochemical (IHC) loss of SDHB is a marker of malignancy in pheocromocytomas and paragangliomas.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Md, PhD Massimo Milione
Keywords: midgut, SDHB